China Pharmaceutical Market to Reach USD 573.0 Billion by 2033 CAGR, 7.20% 2025-2033

Market Overview

The China pharmaceutical market size reached USD 306.5 Billion in 2024 and is projected to grow to USD 573.0 Billion by 2033. The market is expected to expand at a CAGR of 7.20% during the forecast period of 2025-2033. Strong drivers include the rising geriatric population and increased healthcare infrastructure.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

China Pharmaceutical Market Key Takeaways

• Current Market Size: USD 306.5 Billion in 2024
• CAGR: 7.20% during 2025-2033
• Forecast Period: 2025-2033
• The market is driven by the rising geriatric population vulnerable to chronic diseases such as diabetes and cancer.
• Increasing number of healthcare facilities with 39,000 reported hospitals in 2023 fueling pharmaceutical demand.
• Chinese pharmaceutical firms are expanding their international footprint through licensing and acquisitions.
• Growth of e-commerce and digital drug sales platforms like JD Health and Alibaba Health enhances accessibility.
• Biologics segment is gaining importance, supported by government initiatives for high-end biopharma production.

Sample Request Link:

https://www.imarcgroup.com/china-pharmaceutical-market/requestsample

Market Growth Factors

As the proportion of senior citizens in China increases, so do the pharmaceutical demands of this demographic. The elderly in China are more likely to develop chronic diseases such as diabetes, cardiovascular & cerebrovascular diseases and cancer and better understand the need for early diagnosis and treatment. Easy administration, fewer side effects, and cheaper formulations are driving the market growth for drugs designed to be used by the elderly population.

As of 2023, China had about 39000 hospitals. The number of hospitals, outpatient medical clinics, surgical sites, and nursing homes has been constantly increasing, leading to more demand and consumption of pharmaceutical products. Investments in medical devices, diagnostic equipment, and tax incentives for biotech companies have increased healthcare infrastructure.

Chinese pharmaceutical companies are growing to Europe, Southeast Asia and Latin America by licensing, acquisitions, and joint ventures. The Chinese government encourages overseas investment and growth in foreign markets for generics, biosimilars, and special medicines (such as HIV, diabetes, osteoporosis and orphan drugs), as evidenced by faster drug approvals in overseas markets such as the US (FDA) and Europe (EMA). Private companies are exporting oncology and autoimmune disease products.

Market Segmentation

Type:

• Pharmaceutical Drugs: Includes cardiovascular, dermatology, gastrointestinal, genito-urinary, hematology, anti-infective, metabolic disorder, musculoskeletal disorder, central nervous system, oncology, ophthalmology, and respiratory disease drugs.
• Biologics: Encompasses monoclonal antibodies (MAbs), therapeutic proteins, and vaccines.

Nature:

• Organic
• Conventional

Region:

• North China
• East China
• South Central China
• Southwest China
• Northwest China
• Northeast China

Request Customization:

https://www.imarcgroup.com/request?type=report&id=23447&flag=E

Regional Insights

The report identifies several key regions: North China, East China, South Central China, Southwest China, Northwest China, and Northeast China. While specific market share statistics are not provided, the segmentation indicates focus across these dominant regions in China's pharmaceutical industry, reflecting broad geographic distribution of market activities.

Recent Developments & News

• 01 August 2025: Ascentage Pharma announced participation in the Evercore China Biotech Summit in Shanghai from August 19-21, 2025, with management engaging in investor discussions.
• 28 July 2025: Neuco United and Fosun Pharma signed an exclusive licensing deal for AR1001, an Alzheimer's therapy, aiming to leverage Fosun's strengths for Chinese patients; AR1001 is in Phase III trials.
• 20 March 2024: Sinopharm entered a strategic cooperation agreement with Fresenius Kabi (China) Co Ltd to enhance pharmaceutical sales, warehousing, and healthcare services.
• 30 October 2023: Jiangsu Hengrui Pharmaceuticals partnered with Merck for exclusive worldwide rights to develop and commercialize PARP1 inhibitor HRS-1167 and Claudin-18.2 antibody-drug conjugate SHR-A1904.

Key Players

• Ascentage Pharma
• Neuco United
• Fosun Pharma
• AriBio
• Sinopharm
• Fresenius Kabi (China) Co Ltd
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Merck

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302

About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.